Pathological analysis of hesperetin-derived small cell lung cancer by artificial intelligence technology under fiberoptic bronchoscopy

Xiaoli Zhang; Ziying Yu; Xiaoli Zhang; Ziying Yu

doi:10.3934/mbe.2021423

Mathematical Biosciences and Engineering

2021, Volume 18, Issue 6: 8538-8558. doi: 10.3934/mbe.2021423

Previous Article Next Article

Research article Special Issues

Pathological analysis of hesperetin-derived small cell lung cancer by artificial intelligence technology under fiberoptic bronchoscopy

Xiaoli Zhang ¹,
Ziying Yu ^{2
,
,}

1.
Department of Pathology, The First Affiliated Hospital of University of South China, Hengyang 421001, China
2.
Department of Emergency, The First Affiliated Hospital of University of South China, Hengyang 421001, China

Academic Editor: Zhihan Lv

Received: 30 July 2021 Accepted: 13 September 2021 Published: 30 September 2021

Lung cancer is one of the most common tumors. There are 1.8 million new cases worldwide each year, accounting for about 13% of all new tumors. Lung cancer is the most important cause of cancer-related deaths. 1.4 million people die of lung cancer each year. This article uses artificial intelligence technology to analyze the pathology of hesperetin-derived small cell lung cancer under fiberoptic bronchoscopy. This article takes 48 lung slice samples as the research object. Among them, 36 cases of lung small cell carcinoma have history slices from Lhasa City Institute of Biology, the patient has complete cases, and the other 12 normal lung slices come from Xinjiang Biotechnology Laboratory. In this paper, the above-mentioned 36 lung cancer slices became the study group, and 12 normal slices became the reference group. This article presents a method for hesperetin-fiber bronchoscope to study the pathological mechanism of lung small cell carcinoma (H-FBS), which is used to study slices. The above-mentioned 48 samples were taken for slice observation. First, the 48 slices were technically tested by artificial intelligence fiber bronchoscope combined with hesperetin derivatives, and then the slice observation results were verified by CTC technology. In addition, in each step, the C5orf34 in the tissue is detected separately, which is beneficial to adjust the content of C5orf34 so that the treatment of lung cancer can control the development of lung cancer under fiberoptic bronchoscopy. Experimental results show that the diagnostic accuracy rate of this method is 97.9%, which is higher than that of lung biopsy (89%); compared with multiple CTC detection, the cost is low and the time is shor.
- hesperetin derivatives,
- lung small cell carcinoma,
- circulating cell detection technology,
- fiberoptic bronchoscopy
Citation: Xiaoli Zhang, Ziying Yu. Pathological analysis of hesperetin-derived small cell lung cancer by artificial intelligence technology under fiberoptic bronchoscopy[J]. Mathematical Biosciences and Engineering, 2021, 18(6): 8538-8558. doi: 10.3934/mbe.2021423

Related Papers:

Abstract

Lung cancer is one of the most common tumors. There are 1.8 million new cases worldwide each year, accounting for about 13% of all new tumors. Lung cancer is the most important cause of cancer-related deaths. 1.4 million people die of lung cancer each year. This article uses artificial intelligence technology to analyze the pathology of hesperetin-derived small cell lung cancer under fiberoptic bronchoscopy. This article takes 48 lung slice samples as the research object. Among them, 36 cases of lung small cell carcinoma have history slices from Lhasa City Institute of Biology, the patient has complete cases, and the other 12 normal lung slices come from Xinjiang Biotechnology Laboratory. In this paper, the above-mentioned 36 lung cancer slices became the study group, and 12 normal slices became the reference group. This article presents a method for hesperetin-fiber bronchoscope to study the pathological mechanism of lung small cell carcinoma (H-FBS), which is used to study slices. The above-mentioned 48 samples were taken for slice observation. First, the 48 slices were technically tested by artificial intelligence fiber bronchoscope combined with hesperetin derivatives, and then the slice observation results were verified by CTC technology. In addition, in each step, the C5orf34 in the tissue is detected separately, which is beneficial to adjust the content of C5orf34 so that the treatment of lung cancer can control the development of lung cancer under fiberoptic bronchoscopy. Experimental results show that the diagnostic accuracy rate of this method is 97.9%, which is higher than that of lung biopsy (89%); compared with multiple CTC detection, the cost is low and the time is shor.

References

[1]	O. Arrieta, Z. L. Zatarain-Barrón, A. F. Cardona, New opportunities in a challenging disease: Lurbinectedin for relapsed small-cell lung cancer, Lancet Oncol., 21 (2020), 605-607. doi: 10.1016/S1470-2045(20)30097-8
[2]	M. Dómine, T. Moran, D. Isla, J. L. Martí, I. Sullivan, M. Provencio, et al., SEOM clinical guidelines for the treatment of small‑cell lung cancer (SCLC) (2019), 22 (2020), 245-255.
[3]	J. Trigo, V. Subbiah, B. Besse, V. Moreno, R. López, M. A. Sala, et al. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial, Lancet Oncol., 21 (2020), 645-654.
[4]	B. J. Morrison, J. C. Morris, J. C. Steel, Lung cancer-initiating cells: a novel target for cancer tlierapy, Targeted Oncol., 8 (2013), 159-172. doi: 10.1007/s11523-012-0247-4
[5]	V. S. Donnenberg, A. D. Donnenberg, Multiple drug resistance in cancer revisited: the cancer stem cell hypothesis, J. Clin. Pharmacol., 45 (2005), 872-877. doi: 10.1177/0091270005276905
[6]	G. Gehling, B. Beck, A. Caauwe, B. D. Simons, Defining the mode of tumour growth by clonal analysis, Nature, 488 (2012), 527-530. doi: 10.1038/nature11344
[7]	H. T. Neagu, c-Kit expression in human normal and malignant stem cells prognostic and therapeutic implications, Leuk. Res., 33 (2009), 5-10. doi: 10.1016/j.leukres.2008.06.011
[8]	D. Burgos-Ojeda, B. R. Rueda, R. J. Buckanovich, Ovarian cancer stem cell markers: prognostic and therapeutic implications, Cancer Lett., 322 (2012), 1-7. doi: 10.1016/j.canlet.2012.02.002
[9]	S. Ali, S. Ali, Role of c-kit/SCF in cause and treatment of gastronintestinal stomal tumors (GIST), Gene, 40 (2007), 38-45.
[10]	L. Boldrini, S. Ursino, S. Gisfredi, P. Faviana, V. Donati, T. Camacci, et al., Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance, Clin. Cancer Res., 10 (2004), 4101-4108. doi: 10.1158/1078-0432.CCR-03-0664
[11]	G. Karoubi, L. Cortes-Dericks, M. Gugger, D. Galetta, L. Spaggiari, R. A. Schmid, Atypical expression and distribution of embryonic stem cell marker, OCt4, in human lung adenocarcinoma, J. Surg. Oncol., 102 (2010), 689-698.
[12]	X. Zhang, B. Han, J. Huang, B. Zheng, Q. Geng, F. Aziz, et al., Prognostic significance of OTC4 expression in adenocarcinoma of the lung, Jpn. J. Clin. Oncol., 40 (2010), 960-966.
[13]	L. M. Sholl, K. B. Long, J. L. Hornick, SOX2 expression in pulmonary non-small cell and neuroendocrine carcinomas, Appl. Immunohistochem. Mol. Morphol., 18 (2020), 55-61.
[14]	T. Hussenet, S. du Manoir, SOX2 in squamous cell carcinoma: amplifying a pleiotropic oncogene along carcinogenesis, Cell Cycle, 9 (2010), 1480-1486.
[15]	K. C. Chou, The problem of Elsevier series journals online submission by using artificial intelligence, Nat. Sci., 12 (2020), 37-38.
[16]	C. J. Langer, V. Hirsh, A. Ko, M. F. Renschler, M. A. Socinski, Weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: analysis of safety and efficacy in patients with renal impairment, Clin. Lung Cancer, 16 (2015), 112-120. doi: 10.1016/j.cllc.2014.09.003
[17]	D. W. Cockcroft, H. Gault, Prediction of creatinine clearance from serum creatinine, Nephron, 16 (1976), 31-41. doi: 10.1159/000180580
[18]	H. G. Eichler, S. X. Kong, W. C. Gerth, P. Mavros, B. Jönsson, Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge?, Value Heal, 7 (2004), 518-528. doi: 10.1111/j.1524-4733.2004.75003.x
[19]	H. Tan, J. Hu, S. Liu, Efficacy and safety of nanoparticle albumin-bound paclitaxel in non-small cell lung cancer: a systematic review and meta-analysis, Artif. Cells Nanomed. Biotechnol., 47 (2019), 268-277. doi: 10.1080/21691401.2018.1552595
[20]	E. R. Gardner, W. L. Dahut, C. D. Scripture, J. Jones, J. B. Aragon-Ching, N. Desai, et al., Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel, Clin. Cancer Res., 14 (2008), 4200-4205. doi: 10.1158/1078-0432.CCR-07-4592
[21]	M. A. Socinski, I. Bondarenko, N. A. Karaseva, A. M. Makhson, I. Vynnychenko, I. Okamoto, et al., Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial, J. Clin. Oncol., 30 (2012), 2055-2062. doi: 10.1200/JCO.2011.39.5848
[22]	F. Bray, J. Ferlay, I. Soerjomataram, R. L. Siegel, L. A. Torre, A. Jemal, Globalcancer statistics 2018: GLOBOCAN estimates of incidence andmortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin., 68 (2018), 394-424. doi: 10.3322/caac.21492
[23]	F. M. Watzka, C. Fottner, M. Miederer, A. Schad, M. M. Weber, G. Otto, et al., Surgi-cal therapy of neuroendocrine neoplasm with hepatic metasta-sis: patient selection and prognosis, Langenbecks Arch. Surg., 400 (2015), 349-358. doi: 10.1007/s00423-015-1277-z
[24]	J. F. Gainor, A. M. Varghese, S. H. I. Ou, S. Kabraji, M. M. Awad, R. Katayama, et al., ALK rear-rangements are mutually exclusive with mutations in EGFR orKRAS:an analysis of 1 683patients with non-small cell lungcancer, Clin. Cancer Res., 19 (2013), 4273-4281. doi: 10.1158/1078-0432.CCR-13-0318
[25]	A. T. Shaw, B. Y. Yeap, M. Mino-Kenudson, S. R. Digumarthy, D. B. Costa, R. S. Heist, et al., Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK, J. Clin. Oncol., 27 (2009), 4247-4253. doi: 10.1200/JCO.2009.22.6993

Reader Comments

Your name:*

Email:*
© 2021 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)